T0	Participants 86 124	advanced epithelial ovarian carcinoma.
T1	Participants 182 386	patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen.
T2	Participants 408 472	Patients with bidimensionally measurable disease were randomised
T3	Participants 946 969	A total of 226 patients
T4	Participants 1822 1859	group of patients receiving topotecan
T5	Participants 1863 1889	relapse of ovarian cancer.